Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
Conclusion: Our analysis of FAERS database provided postmarketing surveillance data and revealed different strengths of reported AE signals between Dmab and ZA in some of their common AEs. It’s also worth noting that both drugs have potential off-label applications, which could introduce new AEs. This highlights the necessity for safety monitoring when using Dmab and ZA off-label. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - November 1, 2023 Category: Drugs & Pharmacology Source Type: research
Zoledronic acid
(Source: Reactions Weekly)
Source: Reactions Weekly - November 1, 2023 Category: Drugs & Pharmacology Source Type: research
Five-Year Outcomes of Continuous Zoledronic Acid vs. Denosumab Treatment in Older Men with High Fracture Risk: Effects on Bone Density Improvement and Risk Factor Analysis of Improvement of Bone Density and Incidence of New Fracture
This study investigated the treatment efficacy of these agents in older male patients with low a bone mass and history of fragility fracture. 175 male patients receiving continuous zoledronic acid treatment and 366 male patients receiving continuous denosumab treatment at our medical center between 2015 and 2020 were included and we analyzed the efficacy of treatment from the improvement in bone mineral density (BMD) and the new-onset low-energy fracture rate after 5 years of continuous medication from their data. BMD significantly improved after 5 years of medication, and higher than 90% patients were satisfied with their...
Source: The Journal of Clinical Pharmacology - October 28, 2023 Category: Drugs & Pharmacology Authors: Tong-Che Wu Yun-Jui Tsou Wen-Tien Wu Ru-Ping Lee Jen-Hung Wang Kuang-Ting Yeh Source Type: research
Five-Year Outcomes of Continuous Zoledronic Acid vs. Denosumab Treatment in Older Men with High Fracture Risk: Effects on Bone Density Improvement and Risk Factor Analysis of Improvement of Bone Density and Incidence of New Fracture
This study investigated the treatment efficacy of these agents in older male patients with low a bone mass and history of fragility fracture. 175 male patients receiving continuous zoledronic acid treatment and 366 male patients receiving continuous denosumab treatment at our medical center between 2015 and 2020 were included and we analyzed the efficacy of treatment from the improvement in bone mineral density (BMD) and the new-onset low-energy fracture rate after 5 years of continuous medication from their data. BMD significantly improved after 5 years of medication, and higher than 90% patients were satisfied with their...
Source: The Journal of Clinical Pharmacology - October 28, 2023 Category: Drugs & Pharmacology Authors: Tong-Che Wu Yun-Jui Tsou Wen-Tien Wu Ru-Ping Lee Jen-Hung Wang Kuang-Ting Yeh Source Type: research
Five-Year Outcomes of Continuous Zoledronic Acid vs. Denosumab Treatment in Older Men with High Fracture Risk: Effects on Bone Density Improvement and Risk Factor Analysis of Improvement of Bone Density and Incidence of New Fracture
This study investigated the treatment efficacy of these agents in older male patients with low a bone mass and history of fragility fracture. 175 male patients receiving continuous zoledronic acid treatment and 366 male patients receiving continuous denosumab treatment at our medical center between 2015 and 2020 were included and we analyzed the efficacy of treatment from the improvement in bone mineral density (BMD) and the new-onset low-energy fracture rate after 5 years of continuous medication from their data. BMD significantly improved after 5 years of medication, and higher than 90% patients were satisfied with their...
Source: The Journal of Clinical Pharmacology - October 28, 2023 Category: Drugs & Pharmacology Authors: Tong-Che Wu Yun-Jui Tsou Wen-Tien Wu Ru-Ping Lee Jen-Hung Wang Kuang-Ting Yeh Source Type: research
Five-Year Outcomes of Continuous Zoledronic Acid vs. Denosumab Treatment in Older Men with High Fracture Risk: Effects on Bone Density Improvement and Risk Factor Analysis of Improvement of Bone Density and Incidence of New Fracture
This study investigated the treatment efficacy of these agents in older male patients with low a bone mass and history of fragility fracture. 175 male patients receiving continuous zoledronic acid treatment and 366 male patients receiving continuous denosumab treatment at our medical center between 2015 and 2020 were included and we analyzed the efficacy of treatment from the improvement in bone mineral density (BMD) and the new-onset low-energy fracture rate after 5 years of continuous medication from their data. BMD significantly improved after 5 years of medication, and higher than 90% patients were satisfied with their...
Source: The Journal of Clinical Pharmacology - October 28, 2023 Category: Drugs & Pharmacology Authors: Tong-Che Wu Yun-Jui Tsou Wen-Tien Wu Ru-Ping Lee Jen-Hung Wang Kuang-Ting Yeh Source Type: research
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors
Bone is a frequent metastatic site in advanced non-small cell lung cancer (aNSCLC), with up to 40 % of patients harboring bone metastases (BM) at diagnosis [1–3]. Bone targeted agents (BTA) – such as zoledronic acid and denosumab – demonstrated to prevent and/or delay the occurrence of skeletal related events (SRE) in patients with BM, with a manageable toxicity profile and a significan t benefit also in terms of quality of life [4–7]. (Source: Lung Cancer)
Source: Lung Cancer - October 27, 2023 Category: Cancer & Oncology Authors: Sara Manglaviti, Marta Bini, Giulia Apollonio, Ernesto Zecca, Giulia Galli, Sabina Sangaletti, Alice Labianca, Elisa Sottotetti, Marta Brambilla, Mario Occhipinti, Claudia Proto, Arsela Prelaj, Diego Signorelli, Alessandro De Toma, Giuseppe Viscardi, Tere Source Type: research
Global Publication Trends and Research Hotspots of the Immune System and Osteoporosis: A Bibliometric and Visualization Analysis from 2012 to 2022
CONCLUSION: The influence of the immune system on OP has been widely studied, and the current research in this field focuses on the effect or mechanism of immune-related cytokines, signaling pathways and vitamin D on OP. Future research trends in this field should focus on the immune regulation mechanism and clinical transformation of zoledronic acid, chain fatty acids and the gut microbiota in OP.PMID:37881072 | DOI:10.2174/0118715303257269231011073100 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - October 26, 2023 Category: Drugs & Pharmacology Authors: Jinlong Zhao Yaoxing Dou Guihong Liang Hetao Huang Kunhao Hong Weiyi Yang Guanghui Zhou Bangxin Sha Jun Liu Lingfeng Zeng Source Type: research
Global Publication Trends and Research Hotspots of the Immune System and Osteoporosis: A Bibliometric and Visualization Analysis from 2012 to 2022
CONCLUSION: The influence of the immune system on OP has been widely studied, and the current research in this field focuses on the effect or mechanism of immune-related cytokines, signaling pathways and vitamin D on OP. Future research trends in this field should focus on the immune regulation mechanism and clinical transformation of zoledronic acid, chain fatty acids and the gut microbiota in OP.PMID:37881072 | DOI:10.2174/0118715303257269231011073100 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - October 26, 2023 Category: Endocrinology Authors: Jinlong Zhao Yaoxing Dou Guihong Liang Hetao Huang Kunhao Hong Weiyi Yang Guanghui Zhou Bangxin Sha Jun Liu Lingfeng Zeng Source Type: research
Global Publication Trends and Research Hotspots of the Immune System and Osteoporosis: A Bibliometric and Visualization Analysis from 2012 to 2022
CONCLUSION: The influence of the immune system on OP has been widely studied, and the current research in this field focuses on the effect or mechanism of immune-related cytokines, signaling pathways and vitamin D on OP. Future research trends in this field should focus on the immune regulation mechanism and clinical transformation of zoledronic acid, chain fatty acids and the gut microbiota in OP.PMID:37881072 | DOI:10.2174/0118715303257269231011073100 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - October 26, 2023 Category: Drugs & Pharmacology Authors: Jinlong Zhao Yaoxing Dou Guihong Liang Hetao Huang Kunhao Hong Weiyi Yang Guanghui Zhou Bangxin Sha Jun Liu Lingfeng Zeng Source Type: research
Prediction of musculoskeletal pain after the first intravenous zoledronic acid injection in patients with primary osteoporosis: development and evaluation of a new nomogram
To construct a new prediction nomogram to predict the risk of musculoskeletal pain in patients with primary osteoporosis who receive zoledronic acid intravenously for the first time. (Source: BMC Musculoskeletal Disorders)
Source: BMC Musculoskeletal Disorders - October 25, 2023 Category: Orthopaedics Authors: Xiaoxia Zheng, Jiangnan Ye, Qunzhang Zhan, Weifeng Zhao, Zhongqin Liao, Xiaolin Ye and Chongzheng Qu Tags: Research Source Type: research
Growth hormone and testosterone delay vertebral fractures in boys with muscular dystrophy on chronic glucocorticoids
ConclusionGH and testosterone each decreased VF risk in patients independent of or in combination with ZA, respectively. (Source: Osteoporosis International)
Source: Osteoporosis International - October 23, 2023 Category: Orthopaedics Source Type: research
Zoledronic acid add-on therapy for standard-risk Ewing sarcoma patients in the Ewing 2008R1 trial
CONCLUSION: In patients with standard-risk localized EWS, there is no additional benefit from maintenance treatment with ZOL.PMID:37843857 | DOI:10.1158/1078-0432.CCR-23-1966 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 16, 2023 Category: Cancer & Oncology Authors: Raphael Koch Lianne Haveman Ruth Ladenstein B énédicte Brichard Heribert Juergens So ňa Cyprová Henk van den Berg Wolf Hassenpflug Anna Raciborska Torben Ek Daniel Baumhoer Gerlinde Egerer Leo Kager Marleen Renard Peter Hauser Stefan Burdach Judith V Source Type: research
Zoledronic acid add-on therapy for standard-risk Ewing sarcoma patients in the Ewing 2008R1 trial
CONCLUSION: In patients with standard-risk localized EWS, there is no additional benefit from maintenance treatment with ZOL.PMID:37843857 | DOI:10.1158/1078-0432.CCR-23-1966 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 16, 2023 Category: Cancer & Oncology Authors: Raphael Koch Lianne Haveman Ruth Ladenstein B énédicte Brichard Heribert Juergens So ňa Cyprová Henk van den Berg Wolf Hassenpflug Anna Raciborska Torben Ek Daniel Baumhoer Gerlinde Egerer Leo Kager Marleen Renard Peter Hauser Stefan Burdach Judith V Source Type: research
M < sub > 4 < /sub > IDP stimulates ROS elevation through inhibition of mevalonate pathway and pentose phosphate pathway to inhibit colon cancer cells
This study revealed for the first time a possible mechanism of bisphosphonate-induced increase of ROS in malignant tumor cells. This is helpful for the development of new molecular therapeutic targets and can provide new ideas for the combined therapy of bisphosphonates in tumors.PMID:37838274 | DOI:10.1016/j.bcp.2023.115856 (Source: Biochemical Pharmacology)
Source: Biochemical Pharmacology - October 14, 2023 Category: Drugs & Pharmacology Authors: Ying Peng Qing-Zhu Liu Dong Xu Jia-Yu Fu Li-Xia Zhang Ling Qiu Jian-Guo Lin Source Type: research
